Clinical trial on the efficacy and safety of Nobilex 90 to fatty liver

Clinical trial on the efficacy and safety of Nobilex 90 to fatty liver - Clinical trial of Nobilex 90 to fatty liver

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000034957

Enrollment

Registered

2018-11-26

Start date

2018-11-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fatty liver

Interventions

The actual drug group to which Novilex 90 (nobiletin mixture 50 mg) is administered and the place group to which placebo is administered 8 weeks administration

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Increase of liver and kidney contrast on ultrasonography

Exclusion criteria

Exclusion criteria: The liver is untreated

Design outcomes

Primary

Measure	Time frame
Liver ultrasound examination: liver renal contrast, intrahepatic vessel obscurity, deep attenuation	—

Secondary

Measure	Time frame
Blood biochemical test (GOT, GPT, gamma-GTP, T-Bil, LDH, ALP, TP, ALB, BUN, CRE, Adiponectin)	—

Countries

Japan

Contacts

Public ContactKimio Sugaya

Southern Knights' Laboratory Co., Ltd. Southern Knights' Laboratory

sugaya@med.u-ryukyu.ac.jp090-4998-7459

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026